Alcon Inc. Ordinary Shares (ALC)

Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST.

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.53 and core diluted earnings per share2 of $0.81 in the third quarter of 2024.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of PRECISION7®, the only one-week replacement contact lens with the revolutionary 7-day ACTIV-FLO® System2 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase its latest clinical data and product innovations at the upcoming American Academy of Ophthalmology (AAO) 2024 annual meeting. Ophthalmologists, surgical staff, researchers, and industry leaders can visit Alcon at booth #4008 for hands-on demonstrations and engaging experiences.

Shares of Alcon Inc. (NYSEALC) traded at a new 52-week high today and are currently trading at $87.64. So far today, approximately 142.97k shares have been exchanged, as compared to an average 30-day volume of 992.37k shares.

Alcon Inc. (NYSEALC) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 2.4% on the day to $82.17.

The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.45 and core diluted earnings per share2 of $0.74 in the second quarter of 2024.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. These innovations are the first to be introduced from Alcon’s highly anticipated Unity portfolio.

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.50 and core diluted earnings per share2 of $0.78 in the first quarter of 2024.

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM).

STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population

Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.5¤

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2023. For the fourth quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and 10% on a constant currency basis(1), as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.86 and core diluted earnings per share(2) of $0.70 in the fourth quarter of 2023.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED).

Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements

Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2024 J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST.

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2023. For the third quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and 9% on a constant currency basis(1), as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.41 and core diluted earnings per share(2) of $0.66 in the third quarter of 2023.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will continue to demonstrate the company’s commitment to Eye Care Professionals and patients by providing connected equipment ecosystems via its digital innovation efforts at the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting. Ophthalmologists, surgical staff, researchers, and industry leaders will have the opportunity to experience Alcon’s latest digital offerings and participate in additional Alcon events during the conference. Alcon AAO event information and registration is available at MyAlconatAAO.com.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the global launch of TOTAL30® Multifocal, the first and only monthly Water Gradient multifocal contact lens—it feels like nothing even at day 30.1 The lenses have begun to roll out in the United States and in select international markets.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today revealed final data from its Vivity® Registry Study, which monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof® IQ Vivity® or AcrySof® IQ Vivity® Toric presbyopia-correcting intraocular lens (PCIOL). Data from more than 900 cataract patients demonstrated sustained clinical performance, high patient satisfaction and reduced dependence upon spectacles (glasses). Evidence also suggested that AcrySof® IQ Vivity® can be used successfully in a broad range of patients, providing surgeons and patients with additional treatment options.

EQNX::TICKER_START (NASDAQOKYO),NYSE:ALCNYSEALC)(NYSE:BLCONYSEBLCO,(NYSE:JNJNYSE),(OTCQX:RHHBY) EQNX::TICKER_END

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will present a robust lineup of scientific data at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), happening 8-12 Sept. in Vienna, Austria. Alcon will showcase product updates that deliver patient outcomes and operational efficiencies for ophthalmologists and staff, and host events with surgeons sharing their real-world experiences with Alcon’s innovation, at booth #B201. For every attendee’s badge scanned at the Alcon booth, Alcon will further its commitment to environmental sustainability by funding the collection and recycling of 50 plastic bottles in coastal communities as part of its ongoing Plastic Bank partnership. Alcon ESCRS event information and registration is available at MyAlconatESCRS.com.

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six months ended June 30, 2023. For the second quarter of 2023, sales were $2.4 billion, an increase of 9% on a reported basis and 12% on a constant currency basis(1), as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.34 and core diluted earnings per share(2) of $0.69 in the second quarter of 2023.